Cabaletta Bio报告Ree-cel显示,治疗骨髓炎有希望,8个病人中有7个在改善。 Cabaletta Bio reports rese-cel shows promise in treating myositis, with 7 of 8 patients improving.

Cabaletta Bio(一家生物技术公司)宣布其细胞疗法(Rese-cel)在治疗脊髓炎、狼疮和螺旋杆菌等自发免疫疾病方面取得有希望的成果。 Cabaletta Bio, a biotech company, announced promising results for its cell therapy, rese-cel, in treating autoimmune diseases like myositis, lupus, and scleroderma. 八分之七的脊髓炎病人在停止某些药物治疗后出现显著改善。 Seven out of eight myositis patients showed significant improvement after stopping certain medications. 该公司计划在2027年之前申请FDA批准用于肌肉炎中的rese-cel,并将在各种会议上提交最新数据. The company plans to seek FDA approval for rese-cel in myositis by 2027 and will present updated data at various conferences.